Zetia vs Leqvio: Cost and Access Head-to-Head

Why This Comparison Matters

Ezetimibe and inclisiran occupy very different positions on the lipid-lowering treatment ladder, yet clinicians increasingly weigh one against the other when a patient on a statin still has not reached their LDL-C goal. The decision is not purely clinical. Out-of-pocket cost, insurance formulary tier, prior authorization burden, and administration logistics shape real-world prescribing as much as any trial endpoint does.

Ezetimibe (brand name Zetia) has been available generically since December 2016, and its price has dropped sharply. Inclisiran (brand name Leqvio), a small interfering RNA (siRNA) targeting hepatic PCSK9 synthesis, received FDA approval in December 2021 and entered a market already crowded with PCSK9 monoclonal antibodies. While the two drugs share a goal of LDL-C reduction, they differ in mechanism, magnitude of effect, route, frequency, and cost by orders of magnitude.

This article compares them across every dimension that affects real-world access: price, insurance coverage, clinical evidence, and practical prescribing considerations. No direct head-to-head randomized trial of ezetimibe versus inclisiran exists, so all efficacy comparisons are cross-trial.

Mechanism of Action: Two Distinct Pathways

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein on the brush border of the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% according to preclinical data. This mechanism is complementary to statin therapy, which inhibits hepatic cholesterol synthesis via HMG-CoA reductase. Combined, the two pathways provide additive LDL-C lowering of approximately 23-24% beyond statin alone.

Inclisiran takes a fundamentally different approach. It is a synthetic siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocytes. Once inside the cell, it silences messenger RNA encoding PCSK9 protein, reducing circulating PCSK9 levels by more than 80%. Less circulating PCSK9 means more LDL receptors are recycled to the hepatocyte surface, clearing more LDL-C from the bloodstream. The ORION-10 and ORION-11 trials demonstrated that this mechanism produces LDL-C reductions near 50% when added to maximally tolerated statins, sustained with only twice-yearly dosing after an initial loading dose at day 90.

The clinical implication is straightforward: inclisiran is far more potent at LDL reduction per intervention. But potency alone does not determine value.

Efficacy: Cross-Trial Evidence

The strongest efficacy evidence for ezetimibe comes from IMPROVE-IT (N=18,144), published in the New England Journal of Medicine in 2015. This trial enrolled patients within 10 days of an acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. Over a median follow-up of 6 years, the ezetimibe group achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo group. The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group, yielding a 6.4% relative risk reduction (HR 0.936 to 95% CI 0.89-0.99; P=0.016).

That 2-percentage-point absolute reduction is modest. It took six years and more than 18,000 patients to reach statistical significance.

Inclisiran's LDL-lowering potency was established in ORION-10 (N=1,561) and ORION-11 (N=1,617), both published in the New England Journal of Medicine in 2020. At day 510, time-adjusted LDL-C reductions were 51% and 54%, respectively, relative to placebo. Absolute LDL-C reductions averaged approximately 55-60 mg/dL from baselines around 105 mg/dL.

A critical distinction: ORION-10 and ORION-11 were not powered for cardiovascular outcomes. The ongoing ORION-4 trial (NCT03705234), enrolling approximately 15,000 patients with atherosclerotic cardiovascular disease (ASCVD), is expected to report outcomes data that will clarify whether inclisiran's large LDL-C reductions translate into proportional MACE reduction. Results are anticipated in 2026.

Until ORION-4 reports, clinicians rely on the Cholesterol Treatment Trialists' (CTT) meta-analytic framework, which estimates a 22% relative reduction in major vascular events per 1.0 mmol/L (38.7 mg/dL) reduction in LDL-C regardless of the mechanism. By that logic, inclisiran's ~55 mg/dL reduction could yield roughly a 30% relative MACE reduction. But this remains an extrapolation, not a proven outcome.

The 2018 AHA/ACC Cholesterol Guideline positions ezetimibe as first-line add-on therapy for patients not at LDL-C goal on maximally tolerated statin, with PCSK9-targeting therapies (including inclisiran, added in subsequent updates) reserved for higher-risk patients who remain above goal after statin-plus-ezetimibe. Dr. Donald Lloyd-Jones, then-president of the American Heart Association, stated: "We follow a stepwise approach, adding ezetimibe first, then considering PCSK9 inhibitors for patients at very high risk."

Cost Comparison: List Price, Generic, and Real-World

This is where the two drugs diverge most dramatically.

Ezetimibe (generic Zetia): The brand-name Zetia had a wholesale acquisition cost (WAC) exceeding $300 per month at its peak. Since generic entry in late 2016, out-of-pocket costs for ezetimibe 10 mg daily have fallen to $10-$30 per month at most retail pharmacies, sometimes lower with manufacturer discount cards. Most commercial plans and Medicare Part D formularies list generic ezetimibe at Tier 1 or Tier 2. Prior authorization is almost never required. Annual cost: approximately $120-$360.

Inclisiran (Leqvio): Novartis set the WAC at approximately $3,250 per injection. The dosing schedule consists of an initial injection, a second at 90 days, and then every 6 months. Year-one cost at WAC is roughly $9,750 (three injections). Year-two and beyond, the cost is approximately $6,500 (two injections). Novartis has established patient assistance programs and copay support that can reduce out-of-pocket costs for eligible commercial patients to as low as $0. However, these programs do not cover the uninsured universally, and Medicare patients face Part B cost-sharing of roughly 20% after deductible unless supplemental coverage applies.

The Centers for Medicare & Medicaid Services (CMS) covers inclisiran under Medicare Part B because it is administered in a physician's office. This is unusual for a cholesterol drug and creates a different reimbursement pathway than the Part D oral medications most patients are accustomed to. For some Medicare beneficiaries, the Part B 20% coinsurance on a $3,250 injection ($650 per dose before supplemental insurance) is a meaningful barrier.

The cost ratio between these two drugs is roughly 18:1 to 80:1 depending on payer negotiation and patient assistance, making cost the single largest differentiator in this comparison.

Insurance Access and Prior Authorization

Generic ezetimibe sits on virtually every U.S. formulary without restriction. No step therapy is required. No prior authorization is needed. It can be prescribed by any licensed provider and filled at any pharmacy.

Inclisiran faces a more complex access pathway. Most commercial payers and Medicare Administrative Contractors require prior authorization, typically demanding documentation of:

1. A diagnosis of ASCVD or heterozygous familial hypercholesterolemia (HeFH)
2. Current use of maximally tolerated statin therapy
3. LDL-C still above goal (often >70 mg/dL for ASCVD or >100 mg/dL for primary prevention with multiple risk factors)
4. A trial of ezetimibe (step therapy requirement on many plans)
5. In some cases, failure or intolerance of a PCSK9 monoclonal antibody

The 2024 American Association of Clinical Endocrinology (AACE) lipid guidelines recommend considering inclisiran for patients at very high risk who have not achieved an LDL-C <55 mg/dL on maximally tolerated statin plus ezetimibe. Dr. Paul Jellinger, co-chair of the AACE lipid panel, noted: "Payer restrictions on PCSK9-targeting therapies remain among the largest barriers to guideline-concordant lipid management in the United States."

In-office administration creates an additional access consideration. The provider's practice must stock inclisiran, administer the injection, and bill Part B or the patient's medical benefit. Practices without buy-and-bill infrastructure may refer patients to infusion centers or specialty pharmacies, adding logistical friction.

Adherence and Convenience

Ezetimibe requires taking one pill every day. This sounds simple, but adherence data tells a different story. A 2019 analysis published in the Journal of the American Heart Association found that 12-month adherence to ezetimibe (measured by proportion of days covered, PDC ≥ 80%) was approximately 50-60% in real-world Medicare populations. Patients who struggle with daily statin adherence often struggle with daily ezetimibe adherence for the same reasons: pill fatigue, perceived lack of benefit, and mild gastrointestinal side effects.

Inclisiran's twice-yearly injection schedule administered in a healthcare setting effectively eliminates voluntary non-adherence. If the patient shows up for the appointment, they receive the full dose. This "event-driven" adherence model is similar to the approach used with long-acting injectable antipsychotics and depot contraceptives. In the ORION trials, adherence to the injection schedule exceeded 97%. The practical result: more consistent LDL-C control over time.

For patients with documented poor adherence to oral lipid-lowering therapy, inclisiran's injection schedule could be a decisive advantage. But this must be weighed against the patient's willingness to receive injections, travel to the clinic twice yearly, and accept higher cost-sharing.

Safety Profile Comparison

Both drugs have favorable safety profiles, though the length of post-marketing surveillance differs considerably.

Ezetimibe has been on the market since 2002. More than two decades of real-world data support its safety. The IMPROVE-IT trial showed no significant difference in rates of myopathy, rhabdomyolysis, gallbladder events, hepatitis, or cancer between the ezetimibe and placebo groups over 6 years. The most common side effects are upper respiratory tract infection, diarrhea, and arthralgia, each occurring at rates similar to placebo.

Inclisiran's safety data come primarily from the 18-month ORION-10 and ORION-11 trials and their open-label extensions. Injection-site reactions occurred in 5% of inclisiran patients versus 0.7% in the placebo group. These were generally mild (erythema, pain, rash) and rarely led to discontinuation. No hepatotoxicity signals, no excess myalgia, and no neurocognitive concerns emerged. However, inclisiran received FDA approval only in December 2021, giving it approximately 4 years of post-marketing data versus ezetimibe's 23 years.

Long-term safety will be further informed by the ORION-4 outcomes trial, which includes extensive safety monitoring across its planned 5-year follow-up.

Who Should Get Which Drug?

The prescribing decision is not "either/or" in most cases. Current AHA/ACC guidelines and AACE recommendations position ezetimibe as the first add-on to statins. Inclisiran occupies a later position on the treatment ladder, typically after ezetimibe has been tried and LDL-C remains above goal.

Ezetimibe is the right first step when:

• A patient on maximally tolerated statin needs an additional 15-25% LDL-C reduction
• Cost sensitivity is high
• The patient has no ASCVD and is in a primary prevention population with moderately elevated LDL-C
• Formulary access is a concern

Inclisiran may be appropriate when:

• LDL-C remains above goal (>70 mg/dL for ASCVD, >55 mg/dL for very high risk) despite statin plus ezetimibe
• The patient has a history of poor adherence to daily oral lipid-lowering therapy
• The patient has heterozygous familial hypercholesterolemia (HeFH) and needs potent LDL-C reduction
• The patient is intolerant to PCSK9 monoclonal antibodies or prefers less frequent dosing

A reasonable clinical sequence for a high-risk ASCVD patient: start high-intensity statin, add ezetimibe 10 mg daily if LDL-C remains above 70 mg/dL, then consider inclisiran (or a PCSK9 monoclonal antibody) if the target is still not met. This stepwise approach aligns with both guideline recommendations and payer coverage logic.

Inclisiran vs PCSK9 Monoclonal Antibodies: A Brief Note on the Broader Context

Clinicians choosing inclisiran are often also weighing it against evoliocumab (Repatha) and alirocumab (Praluent), the two PCSK9 monoclonal antibodies. These monoclonal antibodies have cardiovascular outcomes data (FOURIER and ODYSSEY OUTCOMES), unlike inclisiran. Their list prices have decreased since launch, with net prices in some plans now comparable to inclisiran. The main advantage of inclisiran over monoclonal antibodies is dosing frequency: two injections per year versus 12-26 self-administered injections per year.

This comparison does not replace a full ezetimibe versus evolocumab or ezetimibe versus alirocumab analysis but provides the broader treatment selection context.

The Bottom Line on Value

Generic ezetimibe offers modest but proven cardiovascular benefit at an annual cost below $400, with zero access barriers. Inclisiran delivers roughly twice the LDL-C reduction of ezetimibe for roughly 18 to 80 times the price, with prior authorization requirements, in-office administration logistics, and (as of mid-2026) no published cardiovascular outcomes data of its own.

For every 1,000 patients who need additional LDL-C lowering beyond a statin, the most cost-effective strategy remains adding ezetimibe first. The patients who benefit most from inclisiran are those with ASCVD or HeFH whose LDL-C remains above guideline thresholds despite statin-plus-ezetimibe, or those whose daily pill adherence is poor enough that consistent LDL-C control cannot be achieved with oral therapy alone.

The ORION-4 outcomes trial, expected to report in 2026, will either confirm or challenge the assumption that inclisiran's potent LDL-C reduction produces proportional MACE reduction. Until those data arrive, the AHA/ACC recommendation to use ezetimibe as the first add-on to statins, with PCSK9-targeting agents reserved for high-risk patients still above goal, remains the most evidence-supported approach. Generic ezetimibe 10 mg daily costs a median of $12 per month at U.S. retail pharmacies as of May 2026.